Acute myeloid leukemia (AML) is a heterogeneous disease caused by mutations in transcriptional regulator genes, but how different mutant regulators shape the chromatin landscape is unclear. Here, we compared the transcriptional networks of two types of AML with chromosomal translocations of the RUNX1 locus that fuse the RUNX1 DNA-binding domain to different regulators, the t(8;21) expressing RUNX1-ETO and the t(3;21) expressing RUNX1-EVI1. Despite containing the same DNA-binding domain, the two fusion proteins display distinct binding patterns, show differences in gene expression and chromatin landscape, and are dependent on different transcription factors. RUNX1-EVI1 directs a stem cell-like transcriptional network reliant on GATA2, whereas that of RUNX1-ETO-expressing cells is more mature and depends on RUNX1. However, both types of AML are dependent on the continuous expression of the fusion proteins. Our data provide a molecular explanation for the differences in clinical prognosis for these types of AML.
In Brief
Loke et al. compare the regulatory signature of two related types of acute myeloid leukemia, t(8;21) expressing RUNX1-ETO and t(3;21) expressing RUNX1-EVI1. Each fusion protein displays a distinct binding pattern and cooperates with different transcription factors to impact the epigenome, but both downregulate the myeloid differentiation regulator C/EBPa.
INTRODUCTION
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Despite improvements in supportive care, outcome typically remains poor for AML patients older than 60 years who are unfit for intensive chemotherapy (Dennis et al., 2015) . AML is highly heterogeneous and has been subdivided according to different categories of disease-causing mutations associated with different therapeutic responses. Subclasses are primarily defined by mutations in transcription factors, epigenetic regulators, and signaling molecules that affect cell growth and transcription factor activity (Cancer Genome Atlas Research Network, 2013; Papaemmanuil et al., 2016) . Consequently, myeloid differentiation is impaired at different developmental stages, and different sets of genes are activated or repressed in distinct subsets of AML. Currently, the molecular details of how specific mutant transcriptional regulator proteins affect different sets of genes, and how such deregulated transcriptional networks impact myeloid differentiation, are unknown.
Mutations involving the hematopoietic master regulator RUNX1 are among the most commonly found abnormalities in AML. RUNX1 is the DNA-binding component of core binding factor (CBF), binding as a dimer with CBFb, which is encoded by another recurrently rearranged gene in AML. The most common category of RUNX1 rearrangement is the product of the t(8;21) chromosomal translocation, RUNX1-ETO, which comprises the RUNX1 DNA-binding domain linked to the almost complete ETO protein (also known as RUNX1T1), which functions as a repressor by recruiting histone deacetylases (Bae et al., 1993; Erickson et al., 1992) ( Figure 1A ). The t(8;21) translocation involves 12% of newly diagnosed younger patients with AML (Grimwade et al., 2010) . RUNX1-ETO leads to a block in myeloid differentiation (Cabezas-Wallscheid et al., 2013; Okuda et al., 1998; Regha et al., 2015) , and its expression is required for leukemic propagation (Dunne et al., 2006; Heidenreich et al., 2003; Martinez et al., 2004; Ptasinska et al., 2012) .
The product of another RUNX1 translocation, t(3;21)(q26;q22), is RUNX1-EVI1, whereby the RUNT domain is fused to the entire EVI1 gene ( Figure 1A ) (Mitani et al., 1994; Nucifora et al., 1994) . EVI1 (also known as MECOM or PRDM3) encodes a dual domain zinc-finger transcription factor with direct DNA-binding activity together with a histone methyl transferase (SET) domain (Morishita et al., 1995) ( Figure 1A ) and is an essential regulator of selfrenewal in hematopoietic stem cells (Goyama et al., 2008) . The t(3;21) translocation is rarely found in patients with de novo AML (Lugthart et al., 2010) and is more commonly found in those with therapy-related myelodysplastic syndrome (MDS)/AML (Rubin et al., 1990) or as a secondary event in the transformation of chronic myelogenous leukemia (CML) from chronic phase to blast crisis (Nukina et al., 2014) .
Although RUNX1-ETO and RUNX1-EVI1 carry the same DNAbinding domain and bind to the same motifs in vitro (Meyers et al., 1993; Tanaka et al., 1995) , the two classes of AML have distinct clinical characteristics. The t (8;21) (B) UCSC genome browser screenshot of DNase-seq and corresponding RNA-seq in two patients with t(3;21) AML, two patients with t(8;21) AML, t(3;21) cell line, and normal CD34 + PBSCs at the MEIS1 locus. An enhancer (Xiang et al., 2014) denoted at +140 kb is accessible in t(3;21) AML and normal CD34 + PBSCs, but not in t(8;21) AML. (C) Clustering based on the strength of correlation between samples of DNase-seq data from cells of two patients with t(3;21), two patients with t(8;21), two independent CD34 + PBSCs, and the t(3;21) SKH-1 cell line.
(D) Correlation clustering of RNA-seq data (as in C) from two t(3;21) patients and the SKH-1 cell line with two t(8;21) patients and two normal CD34 + PBSCs.
(E) DNase-seq profiles spanning 4-kb windows for t(3;21) patient 2, t(8;21) patient 1, and SKH-1 cells. Peaks are ranked from top to bottom in order of increasing relative DNA sequence tag count for peaks identified in t(8;21) patient 1 relative to t(3;21) patient 2. The heatmaps to the right depict the relative expression of genes nearest to each DHS calculated as the ratio of FPKM values for t(3;21) patient 2 (P2) divided by values for t(8;21) patient 1 (P1) or patient 2 (P2).
(F) Venn diagram showing the overlap of DNase-seq peaks between t(3;21) patients (both patients combined) and t(8;21) patients (both patients combined).
(G) De novo motif discovery in distal DHSs unique to t(3;21) as compared to t(8;21) patients and distal DHSs unique to t(8;21) compared to t(3;21) patients (as shown in F). See also Figure S1 . and the 5-year event-free survival for t (3;21) patients is only 14% (Lugthart et al., 2010) . However, animal models with RUNX1-ETO and RUNX1-EVI1 expression do show similarities. Mice carrying RUNX1-EVI1 knocked into the RUNX1 locus display a phenotype similar to the RUNX1-ETO knockin (Maki et al., 2005; Okuda et al., 1998; Yergeau et al., 1997) , as they die at embryonic day 13.5 (E13.5) with a failure of adult hematopoiesis. RUNX1-ETO and RUNX1-EVI1 also both require additional secondary mutations before they can cause AML in mice (Cuenco et al., 2000; Cuenco and Ren, 2001; Yuan et al., 2001 ), but RUNX1-EVI1 promotes a more aggressive leukemia with a reduced latency (Cuenco et al., 2000; Maki et al., 2006; Schessl et al., 2005; Schwieger et al., 2002) . The molecular mechanisms underlying these similarities and differences in tumor pathology and clinical response are unclear. To address these issues, we compared the gene expression profiles as well as the chromatin landscape and transcription factor occupancy patterns of patients carrying the t(8;21) and t(3;21) translocations using global DNase I hypersensitive site (DHS) mapping, digital DNase I footprinting, and chromatin immunoprecipitation sequencing (ChIP-seq). These studies revealed that RUNX1-ETO and RUNX1-EVI1 associate with distinct subsets of regulatory elements that bind different classes of transcription factors and deregulate different sets of genes. As previously observed for RUNX1-ETO, depletion of RUNX1-EVI1 in t(3;21) cells initiates myeloid differentiation, which is linked to the upregulation of genes known to be vital for myeloid differentiation. Importantly, initiation of differentiation in either type of AML requires the presence of the master regulator of terminal myeloid differentiation, C/EBPa. Hence, despite having the same DNA-binding domain, our data show that the two different RUNX1 fusion proteins maintain the block in differentiation via unique gene regulatory networks.
RESULTS t(3;21) and t(8;21) AML Display Different Epigenetic Landscapes and Gene Expression Profiles
In order to obtain a first indication of the similarities and differences in the cistromes regulating gene expression patterns in t(8;21) and t(3;21) AML we mapped the accessible chromatin landscape by identifying all DHSs in purified CD34 + leukemic blast cells of two t(3;21) and two t(8;21) AML patients, two sets of normal CD34 + progenitor cells purified as mobilized peripheral blood stem cells (PBSCs) from peripheral blood, and a t(3;21) cell line derived from a CML patient in blast crisis (SKH-1; Mitani et al., 1994) ). We performed DNase I sequencing (DNase-seq) to identify all DHSs within chromatin as described previously (Ptasinska et al., 2012) , and analyzed gene expression profiles using RNA sequencing (RNA-seq). These comparisons uncovered profound differences in gene expression profiles and DHS patterns between t(8;21) and t(3;21) AML, in particular with HOXA-associated genes such as HOXA9 and its partner gene, MEIS1, which are highly expressed in t(3;21) malignancies, but not in t(8;21) AML (Figures 1B, S1A, and S1B). The SKH-1 cell line proved to be a surprisingly good model of primary t (3;21) , as on average 90% of its DHSs overlapped with each of the two primary AMLs (Figures S1B, S1D, and S1E), despite the fact that all three cell types have a very different mutational background (Table S2) . Correlation clustering analyses showed that DHS and gene expression profiles of t(3;21) and t(8;21) patients clustered separately as two distinct groups (Figures 1C and 1D) and showed differential gene expression and DHS patterns (Figures 1E, 1F , and S1D-S1F). Interestingly, for both DNase-seq and RNA-seq data, t(3;21) cells clustered closer to normal CD34 + cells (PBSCs) than t(8;21) cells ( Figures 1 C and 1D ), suggesting a status close to early progenitor and stem cells for this type of AML. Furthermore, although RUNX, ETS, AP-1, and CTCF motifs were shared between the DNA motifs present within distal DHSs specific for the two patient classes, t(3;21) patients exhibited a specific enrichment for GATA motifs, whereas DHSs specific for t (8;21) were enriched in motifs for CEBP and Ebox-binding factors, as observed previously ( Figure 1G ) (Ptasinska et al., 2014) . In contrast, 90% of DHSs that are common to both t(3;21) and t(8;21) cells were also shared with normal CD34 + PBSCs. Consistent with this finding, DHSs common to both types of AML regulate housekeeping functions ( Figure S1C , right panel).
RUNX1-ETO and RUNX1-EVI1 Are Recruited to an Overlapping but Distinct Set of Binding Sites
The differential enrichment for GATA, CEBP, and E-box motifs prompted us to examine whether the binding patterns of RUNX1-ETO, RUNX1-EVI1, and RUNX1 differ between patient groups or whether the shared RHD DNA-binding domain would lead to similar binding pattern. This question is of significant interest, because RUNX1 and RUNX1-ETO have only one DNAbinding domain, whereas RUNX1-EVI1 has two additional potential DNA-binding domains derived from EVI1 (the zinc-finger domains; Figure 1A ), which can contribute additional DNA specificity. It has been previously shown by in vitro studies that EVI1 binds to the GATA-like sequence GA(C/T)AAGA(T/C)AAGATAA (Delwel et al., 1993) and TGACAAGATAA (Perkins et al., 1991) , which resemble one of the t(3;21)-specific motifs ( Figure 1G ). To investigate the in vivo specificity of the fusion proteins compared to RUNX1, we first generated RUNX1 and RUNX1-EVI1 ChIP-seq data from SKH-1 t(3;21) cells. We then compared these data with previously published RUNX1-ETO and RUNX1 ChIP data from the t(8;21) Kasumi-1 cell line (Ptasinska et al., 2012) , as well as previously published RUNX1-binding data from primary CD34 + cells (Cauchy et al., 2015) . Both t (8;21) and t(3;21) AML co-express their respective fusion proteins together with wild-type RUNX1, but no expression of either EVI1 ( Figure S2A ) or ETO was detected, as reported previously (Mitani et al., 1994; Ptasinska et al., 2014) . ETO and EVI1 antibodies therefore detected the fusion proteins, whereas the C-terminal RUNX1 antibody detected wild-type RUNX1 (Figure S2A, red) . A variety of tools were used in combination to analyze the ChIP datasets to demonstrate that despite similar total numbers of binding sites and genomic distribution, the two fusion proteins and RUNX1 each bind to overlapping but largely distinct sets of binding sites (Figures 2A-2D , S2C, S2G, and S3A). In Figures  2E and S2H , we ranked the RUNX1-ETO and the RUNX1-EVI1 or the respective RUNX1 ChIP peaks according to fold difference along the same genomic coordinates ( Figures 2E, S2G, and S2H) and then plotted the motifs, again along the same coordinates. These analyses show unequivocally that the two fusion proteins as well as RUNX1 show a distinct binding pattern in each cell type and that GATA motifs partition with RUNX1-EVI1, whereas E-box and C/EBP motifs partition with RUNX1-ETO. The same holds true for RUNX1 binding patterns ( Figure S2H ). Here, we also plotted our previously reported RUNX1-binding peaks from normal CD34 + cells alongside (Ptasinska et al., 2014) , supporting the idea that the cistrome of t (3;21) (E) RUNX1-EVI1 ChIP peaks were ranked according to tag count, and RUNX1-ETO peaks were plotted alongside, together with motifs for the indicated transcription factors. See also Figure S2 .
the CSF-1 receptor gene (CSF1R) and the PU.1 gene (SPI1), the two fusion proteins target the same regulatory elements (Figures 3A and S3B) (Himes et al., 2001; Li et al., 2001) . At many other sites the fusion protein binding sites co-localize specifically with alternate sets of other binding motifs ( Figure 2C ), such as GATA motifs in t(3;21) and C/EBP and E-Box sites in t(8;21). We did not detect the longer GATA-like motifs in the RUNX1-EVI1 ChIP-seq peaks identified in the in vitro studies ( Figure S2E ). ChIP experiments in t(8;21) cells have shown that RUNX1-ETO co-associates with a number of hematopoietic regulators such as the E-box-binding protein HEB; the ETS factors ERG, FLI1, and PU.1; and the LMO2/LDB1 complex (Martens et al., 2012; Ptasinska et al., 2014; Sun et al., 2013) . To test whether the GATA motifs in RUNX1-EVI1 peaks were bound by GATA factors, we examined the expression of GATA-family members in t(3;21) and t(8;21) patients and found that GATA2, but not GATA1, was expressed at a higher level in t(3;21) than in t(8;21) ( Figure S3C ). Other GATA factors were not expressed at all (Table S1 ). ChIP experiments demonstrated that RUNX1-EVI1, RUNX1, and GATA2 co-associated within a large population of sequences ( Figures 3A, 3B , and S3D), which were characterized by ETS, RUNX, AP-1, and GATA motifs (Figures 3C and S3E) . To identify other enriched motifs at the binding sites of RUNX1 and the two fusion proteins, we performed a more refined analysis examining the enrichment of multiple motifs at binding sites specific for each factor (see analysis scheme above Figure 3D ) and cell type and then clustered the enrichment pvalues ( Figure 3D ). Such an analysis highlights whether a set of motifs shows a higher enrichment in one cell type as compared to another, indicating the binding of different transcription factors around specific binding sites for each fusion protein and highlighting the relative importance of a transcription factor family in each cell type. For t (8;21) cells, this analysis showed that RUNX1 and RUNX1-ETO sites cluster separately with a strong enrichment of RUNX, C/EBP, and GFI1B motifs for both RUNX1-ETO and RUNX1 peaks (boxed in blue), a selective enrichment of E-box motifs for RUNX1-ETO peaks, and a specific enrichment for ETS family motifs for RUNX1 peaks. In contrast, RUNX1-EVI1 and RUNX1 peaks clustered together in t(3;21), with a strongly enriched motif signature for GATA, STAT, HOXA9, and ETS motifs (boxed in green).
To validate our ChIP data in primary cells, we performed digital DNase I footprinting and identified regions protected from nuclease digestion indicative of transcription factor binding using the Wellington algorithm (Piper et al., 2013) . We then filtered footprints against our cell line ChIP data for RUNX1 (in t(8;21) and t(3;21)), RUNX1-EVI1, and RUNX1-ETO. Finally, we performed a bootstrapping analysis, which highlights the significance of occupied motif co-clustering within windows of 50 bp, and plotted enriched motifs in a co-clustering matrix (Figures 3E, 3F, S3F, and S3G) . These analyses showed that RUNX1-EVI1-binding sites clustered with occupied PU.1/ERG (ETS), AP-1, and GATA motifs, suggesting that they may exist as a complex. This is in line with the fact that EVI1 has been shown to directly interact with the AP-1 family member FOS in several cell lines (Bard-Chapeau et al., 2012) and to co-localize with AP-1 motifs (Glass et al., 2013). In contrast, RUNX1-bound sites in t(3;21) only co-localized with occupied ERG (ETS) motifs in each cell type. However, the picture for RUNX1-ETO binding was different. Occupied RUNX1-ETO-bound sites clustered together with RUNX, ERG, and E-box motifs ( Figure 3D ), highlighting the nature of the RUNX1-ETO complex.
Survival of t(3;21) Cells Depends on the Continuous Expression of GATA2, but Not RUNX1 Our binding data suggested that RUNX1-EVI1 and RUNX1-ETO associate with different transcription factor complexes. Furthermore, such differential binding is also found with the wild-type RUNX1 protein expressed from the non-translocated allele in each AML type, indicating that RUNX1 fulfills different roles in programming the chromatin landscape in each cellular context. It was previously shown that the survival of t(8;21) cells is dependent on the expression of wild-type RUNX1, whereby RUNX1 regulated a complementary set of genes balancing the effects of RUNX1-ETO (Ben-Ami et al., 2013) . We therefore tested whether this was also true for t(3;21) cells. To this end, we treated Kasumi-1 and SKH-1 cells with small interfering RNAs (siRNAs) specific for RUNX1 as well as control siRNAs and measured their survival using staining for the apoptosis marker Annexin V and propidium iodide (PI), which indicates dead cells. Figures 3G,  3H (left), and S3H-S3J demonstrate that after 5 days of knockdown, t(8;21) cells showed in increased cell death as compared to control cells, while SKH-1 cells showed no difference and thus do not require wild-type RUNX1.
Previous studies have shown that the members of the RUNX1-ETO complex (namely LMO2 and ERG) are required for the leukemogenicity of RUNX1-ETO and their survival (Sun et al., 2013) . To gain first insights into whether GATA2 was preferentially required for the survival of t(3;21) cells, we depleted GATA2 in both t(3;21) and t(8;21) cells by siRNA treatment (Figures 3G and 3H, right, and measured their survival using staining for Annexin V and PI. These experiments show a strong increase in the number of apoptotic and dead cells in t(3;21) cells, but not in t(8;21) cells, indicating that GATA2 plays a more important role in the survival of t(3;21) cells than in t(8;21) cells.
Taken together, our data demonstrate that despite sharing the same DNA-binding domain, the two fusion proteins predominantly bind to different genomic sites, co-bind with different partners, and operate within a different chromatin landscape. Moreover, the transcriptional networks regulating the survival of both types of AML depend on different non-mutated transcription factors, with t(8;21) cell depending on RUNX1 and t(3;21) cell being dependent on GATA2.
RUNX1-EVI1 Is Required to Maintain the Undifferentiated Phenotype and Survival of t(3;21) AML The t(8;21) translocation is a driver mutation (Wiemels et al., 2002) , and RUNX1-ETO expression is required to maintain the leukemic phenotype in t(8;21) AML (Dunne et al., 2006) . In contrast, RUNX1-EVI1 is a secondary mutation found in secondary AML and in CML in blast crisis (Nukina et al., 2014; Paquette et al., 2011; Rubin et al., 1987 Rubin et al., , 1990 . We therefore used an siRNA knockdown approach to investigate whether RUNX1-was also required to maintain the full leukemic potential of t(3;21) cells.
Motif
Best match We targeted the siRNA to the junction between RUNX1 and EVI1 to specifically deplete RUNX1-EVI1, but not RUNX1 (Figures S2A and S4A) . We transfected SKH-1 with this siRNA and control siRNA, in parallel with control K562 cells, over a period of 2-14 days ( Figure 4A ). Flow cytometry revealed that SKH-1 cells transfected with RUNX1-EVI1 siRNA, but not control RNA, decreased the expression of the progenitor cell marker CD34 ( Figures 4B and 4C ). SKH-1 cells treated with siRNA, but not K562 cells, showed a diminished growth rate ( Figure 4D ) and started to undergo apoptosis ( Figures S4B and S4C Figure 5D ). Gene set enrichment analysis (GSEA) showed that the cells downregulated a stem cell program after knockdown of RUNX1-EVI1 ( Figures  S5A and S5B ). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis for RUNX1-EVI1 target genes downregulated after RUNX1-EVI1 knockdown highlighted multiple signaling genes, such as PIM1, DUSP1, DUSP6, JAK1, and JAK3 ( Figure 5I ). A parallel analysis of upregulated genes identified CEBPA, KIT, and MPO ( Figure S5F ). A more refined picture was also seen when we analyzed downregulated core genes bound by RUNX1-EVI1, RUNX1, and GATA2 ( Figure 5J ). This analysis again identified genes encoding for factors important for stem cell function such as ERG, WT1, and MEIS1.
C/EBPa Is Required for the Response of t(3;21) Cells to RUNX1-EVI1 Knockdown To identify factors that are involved in driving the differentiation of t(3;21) cells after RUNX1-EVI1 knockdown, we examined the changes in the epigenetic landscape of t(3;21) SKH-1 cells by mapping DHSs in cells treated with a control siRNA or after 10 days of knockdown with a RUNX1-EVI1-specific siRNA (Figure S5C) . Examples of these data are depicted in the genome browser screenshots shown in Figures 6A, 6B, and S6A. We then ranked our DHS data according fold difference in sequence tag count ( Figure S5D ). This analysis revealed three groups of elements: a small group of peaks (group 1) unique for control cells, a large number of shared peaks (group 2), and 2,510 peaks that only appeared after knockdown (group 3). A de novo analysis of DNA motifs in these groups revealed that C/EBP motifs were specifically enriched in the DHSs gained after knockdown ( Figure S5E ). These results were concordant with the downregulation of GATA2 and the upregulation of CEBPA expression after RUNX1-EVI1 knockdown (Figures 5A and 5H) . To examine whether these changes in gene expression and motif composition were reflected in changes of binding of the respective factors, we measured the binding of RUNX1, GATA2, and C/EBPa before and after 10 days of RUNX1-EVI1 knockdown ( Figures 6A, 6B , and S6A show screenshots). These experiments show that RUNX1-EVI1 knockdown did not influence the overall global genomic distribution of binding sites for these factors ( Figure 6C ) and did not influence the binding levels of RUNX1, although there was both a decrease in binding at some sites and increases in binding at others ( Figures 6E and S6B ). GATA2 binding decreased slightly overall and some binding sites were lost ( Figures 6D and S6C ), which can be explained by the lower expression of the GATA2 gene ( Figure 5A ). These findings also demonstrated that GATA2 binding was not categorically dependent on the presence of RUNX1-EVI1. However, C/EBPa binding levels were increased ( Figure 6D and 6E) with a number of new binding sites ( Figure S6D ). An alignment of DNA motifs and the DHS peaks confirmed that following RUNX1-EVI1 knockdown, C/EBP motif containing DHSs increased (group 3) in parallel with a depletion of GATA motif containing DHSs (group 1)( Figure 6F ). In contrast, ERG, RUNX, and AP-1 motifs were relatively evenly distributed ( Figure 6F ). CEBPA upregulation is likely to be caused by the reduction of binding of RUNX1-EVI1 after knockdown with a concomitant increase of the binding of RUNX1 and C/EBPa itself to the CEBPA locus ( Figure S6E ). We next examined whether upregulation of C/EBPa was required for the response to oncogene depletion. To this end, we transduced SKH-1 cells with a lentiviral vector expressing a dominant-negative CEBP peptide (DNCEBP) to block C/EBPa binding (and that of all other C/EBP factors) during knockdown RUNX1-EVI1 by siRNA. The DNCEBP peptide dimerizes with CEBP transcription factors and prevents binding to DNA (Krylov et al., 1995) . Expression of the FLAG-epitope-tagged DNCEBP peptide was confirmed by western blotting ( Figure 7A ). We then treated control and DNCEBP SKH-1 cell lines with RUNX1-EVI1 siRNA ( Figures S7A and S7B ). While RUNX1-EVI1 knockdown decreased CD34 expression and proliferation, coexpression of the DNCEBP peptide rescued the leukemic phenotype ( Figures 7B, 7C , and S7C). Similarly, DNCEBP-expressing cells maintained high expression of HOXA9 after RUNX1-EVI1 knockdown, slowed the decrease of the key stem cell renewal genes GATA2 and MEIS1, and blocked increased expression of the markers of myeloid differentiation CTSG, MPO, and CSF1R (Figures 7D, 7E, and S7B) . ChIP experiments confirmed reduced C/EBPa binding at the corresponding loci after DNCEBP expression ( Figure 7F ). Another interesting finding was that the expression of DNCEBP also reduced the increase in RUNX1 binding at a set of known C/EBP and RUNX1 target genes (Figures 7F and 7G) with a concomitant patient 2 or t(8;21) patient 1, respectively. The heatmap shows the significance of co-localizing footprinted motifs at RUNX1 fusion protein-binding sites for each AML as compared to sampling by chance alone. (G and H) Percentage of Annexin-V-positive cells after 5 days of treatment with a control siRNA (siMM) or with siRNAs specific for RUNX1 and GATA2, respectively, in Kasumi-1 cells (G) and SKH1 cells (H). Each experiment was done at least in triplicate as indicated, and error bars represent SEM. *p < 0.05 and **p < 0.01 by unpaired t test. n.s. not significant. See also Figure S3 . reduction in DNase I accessibility at genes strongly activated by RUNX1-EVI1 knockdown, such as MPO or CTSG, indicating that here, the cooperation of C/EBPa and RUNX1 is required for activation ( Figures 7H and S7D ).
Taken together, as summarized in Figure 7I , our study highlights how specific oncogenic transcription factors differentially program the epigenetic landscape in two types of AML with RUNX1 translocations but share the feature that they are dependent on the expression of the fusion protein and the suppression of C/EBPa to inhibit differentiation.
DISCUSSION
The study presented here used global analyses to investigate differences and similarities between two types of CBF AML: the t(8;21) expressing RUNX1-ETO and the t(3;21) expressing RUNX1-EVI1, which both carry the same RUNX1 DNA-binding domain. Our DHS mapping, digital footprinting experiments, and ChIP assays of patient cells and appropriate patient-derived model cell lines unequivocally determined how (1) the epigenetic and transcriptional profiles of the two types of AML differ and (2) show that the RUNT DNA-binding domain of each fusion protein is not the sole determining factor for the selection of fusion protein-binding sites in the genome. Moreover, each type of AML displays a unique, stable transcriptional network that is dependent on the presence of each fusion protein but requires a different set of associated transcription factors.
t(3;21) and t(8;21) AML Display Alternate Transcriptional Networks
The RUNX1-ETO and RUNX1-EVI1 fusion proteins are both unable to cause leukemia in mice on their own (Cuenco et al., MPO (G) , and CEBPA (H). The graph shows mean and SEM of four independent experiments. n.s., not significant; *p < 0.05; **p < 0.01 (unpaired t test). See also Table S1 . (I) KEGG pathways highlighting genes and pathways that are upregulated after RUNX1-EVI1 knockdown. (J) KEGG pathways highlighting pathways associated with genes with shared binding of GATA2, RUNX1, and RUNX1-EVI1 that are upregulated after RUNX1-EVI1 knockdown. See also Figure S5 . 2000; Okuda et al., 1998) , and they show a different history of tumor development in humans. The t(8;21) translocation is a primary mutation that hits an early stem cell (Miyamoto et al., 2000) , whereas t(3;21) is often found in CML patients after blast crisis, indicating that during tumor initiation, the two fusion proteins encounter a dramatically different chromatin landscape that dictates where they can bind. Previous studies from our laboratory that used an inducible version of RUNX1-ETO expressed in murine myeloid precursor cells demonstrated that the induction of the fusion protein leads to a rapid downregulation of myeloid genes such as Spi1(PU.1) and Cebpa and a concomitant increase in the expression of stem cell genes such as Gata2 and Erg, indicating extensive feed-forward loops driving myelopoiesis (Regha et al., 2015) . It is likely that the same holds true for RUNX1-EVI1, but a different differentiation stage or previous transformation event may be required for the establishment of a stable transformed transcriptional network incorporating the expression of this powerful oncoprotein. (E) Profiles of the DNase-seq and ChIP-seq tag density for the indicated factors in ±4-kb windows centered on DHS for SKH-1 treated with either control or RUNX1-EVI1 siRNA. All peaks were ranked according to the fold change in DNase-seq tag counts between control siRNA and RUNX1-EVI1 siRNA-treated SKH-1 cells.
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(F) Densities of the indicated motifs underlying the same coordinates plotted within ±1-kb windows around the DHS marked with a blue arrow. See also Figure S6 .
The unique transcriptional network maintained by RUNX1-EVI1 explains the difference in clinical outcomes of t(3;21) as compared to t(8;21) AML. RUNX1-EVI1 appears to directly regulate a stem cell program establishing an immature phenotype associated with treatment resistance, (Eppert et al., 2011) , expressing genes (MSI2 and ZEB1) regulating leukemia aggressiveness (Ito et al., 2010; Stavropoulou et al., 2016) . Furthermore, HOXA9 and MEIS1 are both expressed in t(3;21), but not in t(8;21), AML. HOXA9 expression is associated with poor prognosis (Andreeff et al., 2008; Golub et al., 1999) , and is linked to a number of mutational subtypes, including mixed lineage leukemia (MLL) and NUP98 translocations (Collins and Hess, 2016) . MEIS1 expression is also associated with poor prognosis as part of a gene expression pattern seen in HSCs and LSCs (Eppert et al., 2011) . HOXA9 and MEIS1 are often co-expressed in AML (Lawrence et al., 1999) and Hoxa9 requires the co-expression of Meis1 to transform murine bone marrow progenitor cells (Kroon et al., 1998) . This cooperativity can be explained by the identification of a large number of cisregulatory elements that are co-bound by both Hoxa9 and Meis1 (Huang et al., 2012) .
The different gene regulatory networks maintaining the two types of AML involve alternate sets of transcription factors, and they differentially program the chromatin landscape, thus impacting where the fusion proteins bind. Our data show that RUNX1-ETO-binding sites are enriched for occupied ETS/ RUNX/E-box motifs, reflecting the structure of the RUNX1-ETO complex, with the ETS factors ERG and FLI1 in the complex being required for leukemia maintenance and leukemogenesis (Martens et al., 2012; Sun et al., 2013) . The expression of ERG in AML is generally associated with poor prognosis (Diffner et al., 2013) . In contrast, RUNX1-EVI1 co-localizes with bound GATA2 and occupied AP-1 motifs, suggesting association with a different complex. Our data indeed show that high-level GATA2 expression is required for the survival of SKH-1 cells, but not t(8;21) cells, whereas RUNX1 regulates a complementary set of genes and is required for the survival of t(8;21) cells (Ben-Ami et al., 2013) , but not SKH-1 cells (this study). High expression of GATA2 is indeed associated with poor prognosis in pediatric AML (Luesink et al., 2012) , which may contribute to the fact that the t(3;21) is more aggressive than t(8;21). How each CBF fusion protein complex programs the DHS landscape, causing differential expression of members of the each complex, is exemplified by the regulation of GATA2. GATA2 expression is higher in t(3;21) cells than in t(8;21) cells, which can be explained by a differential activity of its cis-regulatory elements. Our data show that a distal GATA2 enhancer, known to upregulate GATA2 expression (Grö schel et al., 2014) , is accessible and bound by RUNX1 in normal CD34 + cells, and by RUNX1 and RUNX1-ETO in t(8;21) patient cells, but neither RUNX1 nor RUNX1-EVI1 binds to this element in t(3;21) cells.
In summary, RUNX1 and both fusion protein complexes bind to AML-type specific cis-regulatory modules, which through auto-regulation of genes encoding complex members initiate the formation of stable gene regulatory networks that ultimately define the behavior of each type of AML (Pimanda and Gö ttgens, 2010).
C/EBPa Is Required for the Differentiation of t(8;21) and t(3;21) AML Cells after Oncoprotein Knockdown Despite the differences between t(3;21) and t(8;21) transcriptional networks, C/EBPa is downregulated in both types of AML, suggesting that it is a critical node by which leukemia is maintained. We show that C/EBPa is directly repressed by both RUNX1-EVI1 and RUNX1-ETO through binding to a recently characterized upstream enhancer (Avellino et al., 2016) . In both t(8;21) and t(3;21) cells, knockdown of the CBF fusion protein leads to upregulation of CEBPA, and our ChIP-seq data directly show that the binding of C/EBPa is affected by the knockdown of both fusion proteins. Conversely, in both AML types, the reduction of C/EBPa-binding activity by either knockdown (Ptasinska et al., 2014) or expression of a dominant-negative version of C/EBP (DNCEBP) blocks myelopoiesis and abolishes the upregulation of genes required for terminal myeloid function (MPO, CSF1R, and CTSG) . This result complements previous data showing that overexpression of CEBPA can overcome the RUNX1-EVI1-mediated differentiation block (Tokita et al., 2007 ). An interesting finding from our study is that that the block of C/EBPa binding also abolishes the establishment of specific DHSs at certain genes and the binding of other transcription factors, including RUNX1. C/EBPa interacts with SWI/SNF nucleosome remodeling complexes, and this interaction is important for the development of adipocytes (Pedersen et al., 2001 ). This ability to initiate a global reprogramming of chromatin structures may be the main driver of C/EBPa-mediated myeloid differentiation, and current experiments focus on the mechanistic details of how this occurs.
Taken together, our study provides an important paradigm for studies aimed at understanding how different leukemic fusion proteins program and interact with the epigenetic landscape in two related but different types of AML. Our data represent a resource that will facilitate global mechanistic studies of the genes, transcription factors, and pathways involved in blocking myeloid differentiation and emphasize that different types of AML, despite being a disease of one specific differentiation pathway, are maintained by highly diverse transcriptional networks. Our study therefore highlights the complexities we have to face in our understanding of AML heterogeneity if we want to use this knowledge to devise AML-specific therapies.
EXPERIMENTAL PROCEDURES
Purification of Leukemic Cells and Mobilized Peripheral Stem Cells Cells were purified as described previously (Cauchy et al., 2015) , with minor modifications as outlined in in Supplemental Experimental Procedures.
siRNA-Mediated Depletion 1 3 10 7 cells were electroporated using an EPI 3500 (Fischer) at 350 V, 10 ms.
siRNA sequences are listed in the Supplemental Experimental Procedures. siRNA was used at 200 nM. After electroporation, the cells remained in their cuvettes for 5 min before being directly added to RPMI-1640 with 10% fetal calf serum (FCS), supplemented with penicillin/streptomycin and glutamine at a concentration of 0.5 3 10 6 cells/mL, returned to an incubator, and kept at 37 C and 5% CO 2 .
DHS Mapping, ChIP-Seq, and Digital Footprinting DHS mapping, ChIP-seq, and digital footprinting using the Wellington algorithm (Piper et al., 2013) was performed as described previously (Cauchy 
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Cell Tables S3 and S4 . Sequencing read data and list of peak numbers can be found in Table S3 .
Data Analysis
Details of data analyses can be found in Supplemental Experimental Procedures.
Patient Samples
All human tissue was obtained with the required ethical approval from the National Health Service (NHS) National Research Ethics Committee. Detailed information about patient samples is listed in Table S2 .
ACCESSION NUMBERS
The accession number for all t(3;21) next generation sequencing data reported in this paper is GEO: GSE87286. (E) HOXA9. mRNA levels relative to GAPDH in either empty vector or DNCEBP vector transduced SKH-1 after either control or RUNX1-EVI1 siRNA transfection (4, 10, or 14 days of treatment). The graph shows mean and SEM of three independent experiments. n.s., not significant; *p < 0.05; **p < 0.01 (unpaired t test).
SUPPLEMENTAL INFORMATION
(F and G) ChIP-qPCR with chromatin from empty or DNCEBP vector transduced SKH-1 10 days after either control or RUNX1-EVI1 siRNA transfection, using amplicons corresponding to the MPO and SIGLEC1 enhancers, TREM1 and CTSG promoters, the SPI1 3 0 upstream regulatory element (URE) enhancer as a positive control, and chromosome 18 as a negative control. (F) C/EBPa ChIP. (G) RUNX1 ChIP. Enrichment was calculated relative to input and IVL. Mean of three independent experiments is shown, and error bars represent SEM. n.s., not significant; *p < 0.05; **p < 0.01 (unpaired t test).
(H) DNase I accessibility measurement using qPCR validation at MPO and SIGLEC1 enhancer and TREM1 and CTSG promoter. DNase I digestion was performed on empty vector and DNCEBP vector transduced SKH-1 following either control or RUNX1-EVI1 siRNA transfection. The ACTB amplicon was used as negative control. Enrichment was calculated relative to chromosome 18, which is a gene-free region that is DNase I inaccessible and used for normalization. A second independent experiment is shown in Figure S7D .
(I) Model depicting the binding sites and transcription factors interacting with RUNX1-ETO and RUNX1-EVI1, respectively, and their independent transcriptional networks that maintain the expression of stem cell/precursor genes but also block the expression of CEBPA. See also Figure S7 . RefSeq Genes GATA2 GATA2 GATA2 GATA2-AS1 A-B) UCSC genome browser screenshots of DNase-Seq and the corresponding RNA-Seq aligned reads from two patients with t(3;21) AML, two patients with t(8;21) AML, the t(3;21) cell line SKH-1, and normal CD34+ PBSCs. The regions depicted here span the HOXA9/HOXA10 loci and the GATA2 locus. The HOXA9 and HOXA10 loci include DHSs present in t(3;21) cells but not in t(8;21), whereas the GATA2 encompass DHSs present in t(8;21) cells but not t (3;21) Clustering is based on the differential expression of genes in each patient sample, and reveals that patients with t(3;21) leukemia cluster apart from patients with t(8;21) leukemia. Figure 2) A) Western blot analyses of nuclear extracts from: t(3;21) SKH-1 cells (untreated or transfected with control siRNA or RUNX1-EVI1 siRNA), HEK293T cells (transfected with either empty vector or RUNX1-EVI1 vector as size control), and t(8;21) Kasumi-1 cells. Sizes in kDalton are shown on the left of the blot. Western were blots probed with either an anti-EVI1 or an anti-RUNX1 (N-terminal epitope antibody). Anti-EVI1 and anti-RUNX1 (N-terminal epitope) antibody labels a RUNX1-EVI1 specific band (black arrow). This band is absent in SKH-1 transfected with a RUNX1-EVI1 specific siRNA and is present in HEK293T cells only when transfected with a RUNX1-EVI1 plasmid. In Kasumi-1 nuclear extract, EVI1 antibody does not detect anything, whilst the N-terminal RUNX1 antibody detects RUNX1-ETO (which I) RUNX1 mRNA levels after RUNX1 knockdown in the indicated cell types, relative to GAPDH expression. Graph of mean and error bars indicate the SD between three independent experiments. J) GATA2 mRNA levels after GATA2 knockdown relative to GAPDH expression in the indicated cell types. Graph of mean and error bars indicate the SD between three independent experiments.
Supplemental Figure 2 (related to
Supplemental Figure 4 (related to Figure 4)
A) RUNX1-EVI1 mRNA decreases in SKH-1 cells treated with RUNX1-EVI1 siRNA, as compared to control siRNA treatment. RUNX1 mRNA levels are unaffected by RUNX1-EVI1 siRNA as compared to control siRNA. RT-qPCR showing mRNA levels relative to GAPDH and normalized to untreated cells. RUNX1-EVI1 or RUNX1 mRNA levels in SKH-1 transfected with either specific RUNX1-EVI1 siRNA or control siRNA. Graph of mean and SEM of 4 independent experiments. n.s. not significant, * p<0.05 by unpaired t-test. 
Correlation E Key: siMM: control siRNA siREVI1: RUNX1-EVI1 siRNA * * * after 14 days with electroporation alone or, either, control siRNA or RUNX1-EVI1 siRNA transfection. B) Percentage of Annexin V stained cells. Graph of mean and SEM of at least 3 independent experiments. ** denotes p<0.01 by paired t-test. Representative flow cytometry plots shown in C). D) CD14 expression on SKH-1 cells is unchanged following RUNX1-EVI1 knockdown. Flow cytometric analysis of t(3;21) SKH-1 cells stained with CD14-FITC: untreated, with either electroporation alone or, control or RUNX1-EVI1 siRNA transfection. MFI (median) of CD14 FITC relative to untreated SKH-1 after14 days of treatment. Graph of mean and SEM of 6 independent experiments. E) Clustering analysis of RNA-Seq data from of SKH-1 treated with either control siRNA or RUNX1-EVI1 siRNA. RNA was extracted either after 2, 4 or 10 days of treatment as indicated. Hierarchical clustering of Pearson correlation coefficient between two biological replicates (#1 and #2) of each treatment conditions (siMM: control siRNA; siREVI1: RUNX1-EVI1 siRNA) was performed. Independent replicates cluster together but there are also three major clusters: samples from day 2 time point (both control siRNA and RUNX1-EVI1 siRNA treated samples), samples from control siRNA treated samples at day 4 and 10, and samples from RUNX1-EVI1 siRNA treated samples at day 4 and day 10.
F) RT-qPCR measurements of mRNA levels of MPO, RUNX1, CEBPA, GATA2 and MEIS1, relative to GAPDH and normalized to untreated cells are unchanged in K562 cells after RUNX1-EVI1 siRNA as compared to control siRNA transfection. Graph of mean and SEM of 3 independent experiments. n.s. not significant by unpaired t-test. De novo motifs (group2) De novo motifs (group3) D) Heatmap ranking according to sequence tag counts showing DHS profiles after either control siRNA or RUNX1-EVI1 siRNA transfection. Group 1 -3 identify peaks which are control siRNA-specific, unchanged or RUNX1-EVI1 siRNA specific, respectively. E) Enriched transcription factor binding motifs in group 2 and 3 peaks defined in (D) highlighting the appearance of C/EBP motifs after RUNX1-EVI1knock-down.
F) KEGG pathway for RUNX1-EVI1 ChIP-seq target genes whose expression is upregulated at least 1.5 fold, between RUNX1-EVI1 siRNA and control siRNA treated cells (10 days of treatment), as identified by RNA-seq.
Supplemental Figure 6 (related to Figure 6 ) Figure S6 A control siRNA specific distal peaks shared distal peaks RUNX1-EVI1 siRNA specific distal peaks (E) UCSC browser screenshot depicting transcription factor binding (RUNX1-EVI1, RUNX1 and C/EBPα) to the regulatory elements of the CEBPA locus (boxed in), without (control) and with RUNX1-EVI1 knock-down. 
Purification of blood samples from patients with AML
Blood from t(3;21) patient 1 was diluted 1:1 with PBS and layered onto density gradient medium (Lymphoprep Stem Cell technology, USA). The blood-PBS-lymphoprep mix was subsequently centrifuged at 592xg (acceleration setting 4, no brakes). After centrifugation, the mixture had separated into two phases with the mononuclear cells separated into a layer in between. This middle layer was then isolated and incubated with CD34+ microbeads (Miltenyi-Biotech, USA), according to the manufacturer instructions. The CD34+ expression on this fraction was confirmed by flow cytometry before either immediately use for DNase I hypersensitivity site mapping or RNA extraction by Trizol, as described below.
Cells from t(3;21) patient 2 was previously isolated by density gradient medium and cryopreserved at the Erasmus University Medical Centre, Netherlands. CD34+ cells were thawed with pre-warmed RPMI-1640 +10%FCS. After centrifugation, the cell pellet was resuspended in 750 µl MACS buffer (PBS with 0.5% BSA and 2 mM EDTA) and 35 µl CD34-PE, with a separate sample stained with IgG PE as an isotype control. CD34+ cells were isolated by FACS using a MoFlo Astrios (Beckman Coulter, USA) and were then directly used for DNase I hypersensitivity site mapping or underwent RNA extraction by Trizol, as described below.
Purification of CD34+ mobilized peripheral blood stem cells
CD34+ peripheral blood stem cells (PBSCs) from healthy adults identified by the NHS Blood and Transplant service (NHSBT) were mobilized into the peripheral circulation by administrating donors with pegylated G-CSF (trade name: Lenograstim, Chugai Pharmaceuticals, Japan). Cells were harvested from the patients by apheresis and stored by NHSBT in liquid nitrogen. Cryopreserved cells were thawed at 37ºC using a waterbath and eluted from storage bag with a PBS/Glucose/Citrate solution (0.09% glucose + 3.3% FCS + 1mM sodium citrate). After centrifugation at 300xg for 5 minutes, the cell pellet was treated with DNase I (Roche, Switzerland) at 0.6mg/ml concentration in PBS/Glucose/Magnesium/Calcium solution (PBS+0.5 mM MgCl 2 + 1.2 mM CaCl 2) + 1 % FCS + 0.1 % glucose + 2 mM MgCl 2 ) for 5 minutes at room temperature. Following DNase I treatment the cells were once again diluted with PBS/Glucose/Citrate solution and the mononuclear isolated by density gradient medium and CD34+ beads separation by MACS columns, as described above.
siRNA mediated depletion of RUNX1-EVI1, RUNX1 and GATA2 1x10 7 Kasumi-1 or SKH1 cells were electroporated using a EPI 3500 (Fischer, Germany) electroporation at 350v, 10ms. siRNA sequences (Axolabs, Germany) specific for the translocation breakpoint of Runx1-EVI1 were 5'-GAACCUCGAAAUAAUGAGUGU-3' (sense) and 5'-ACUCAUUAUUUCGAGGUUCUC-3' (antisense). Control siRNA was 5'-CCUCGAAUUCGUUCUGAGAAG-3' (sense) with 5'-UC UCAGAACGAAUUCGAGGUU-3' (antisense). siRNA was used at 200 nM. GATA2 siRNAs (3) were: GATA2 ID 2624, Trilencer-27 Human siRNA, Origene Technologies, Inc. and RUNX1 siRNAs (4) were: ONTARGETplus RUNX1 siRNA, Dharmacon. After electroporation, the cells remained in their cuvettes for 5 minutes before being directly added to RPMI-1640 with 10% FCS, supplemented with penicillin/streptomycin and glutamine at a concentration of 0.5 x10 6 cells per ml and returned to an incubator kept at 37°C and 5% CO 2 .
RNA extraction
Pelleted cells from primary patient material were lysed by adding 1ml Trizol ™ (Life Technologies, US). 200 µl of chloroform was added and the mixture was manually shaken for 15 seconds. The mixture was incubated at room temperature for 3 minutes. The mixture was centrifuged at 12000 x g for 15 minutes at 4°C. The top clear aqueous phase was removed and placed in a fresh tube. 0.5 ml of 100% isopropanol was added to the isolated aqueous phase and incubated at room temperature for 10 minutes which was then transferred to a RNeasy MinElute column (Qiagen, USA) and centrifuged for 15 s at 8000xg. 350 µl of RWI buffer from the RNeasy Kit was added to the column and centrifuged for 15 s at 8000xg. 10 µl DNase I and 70µl RDD buffer (Qiagen, USA) were mixed and added to the column and incubated for 15 minutes at room temperature. Afterwards, 350 µl of RWI buffer from RNeasy Kit (Qiagen, USA) was added to the column and centrifuged for 15s at 8000xg. Following this 500 µl of RPE buffer was added and centrifuged for 15 s at 8000xg. The column was washed with 500 µl 80% ethanol and centrifuged at 2 minutes at 8000xg. The column was dried by centrifuged at 5 minutes at 8000xg. RNA was eluted from the column by adding 12 µl of water to the column followed by centrifugation at 5 minutes at 8000xg.
RNA was isolated from SKH-1 cells by Trizol TM (Life Technologies, US) as by manufacturer's instructions. At the last step of the protocol RNA was resuspended in 17 µl of RNAse free water to which was added 2 µl of 10x buffer supplied with the Ambion Turbo DNase I (Thermos Scientific, USA), of which 1 µl was added. All of which was incubated at 37ºC for 30 minutes. The RNA solution was then purified using a Nucleospin RNA clean up column (Machery Nagel, France), according to their instructions. The quality of RNA from all methods was assessed using a spectrophotometer, by the ratio of the absorbance at 260 nM and 280 nM wavelengths. RNA has a greater absorbance in the 260 nM wavelength, Eukaryotic Total RNA PICO Bioanalyser chip (Agilent technologies, USA) allows visualisation of the size of the RNA molecules and thus, demonstrates whether the sample is degraded or not.
RNA Seq libraries
RNA-Seq libraries were prepared with a Total RNA Ribo-zero library preparation kit (with ribosomal RNA depletion) (Illumina, USA) according to manufacturer's instructions with the following alterations: 15 cycles of PCR was undertaken to amplify the library and adaptors for multiplexing were used at a 1:4 dilution. Library quality was checked by running the samples on a Bioanalyser and libraries were quantified using a Kapa library quantification kit (Kapa Biosystems, USA) and run in a pool of eight indexed libraries in two lane of a HiSeq 2500 (Illumina, USA) using rapid run chemistry with 100bp paired end reads. cDNA synthesis 1µg RNA was used to make cDNA with 0.5 µg OligoDT primer, Murine Moloney Virus reverse transcriptase and RNase Inhibitor (Promega, USA) according to the manufacturer's protocol.
Real-time polymerase chain reaction
RT-PCR was performed using Sybr Green mix (Applied Biosystems, UK), at 2x dilution. Primers were used at 100 nM final concentration. cDNA was diluted either 1:10 or 1:50 depending on expression levels of targets. A 7900HT system (Applied Biosystems, UK) was used to perform qPCR. Analyses were performed in technical duplicates using a standard curve derived from RNA purified from the untreated cell line (1:10 followed by 1:5 dilutions). Primer sequences are listed in the Appendix.
Dead cell removal and Annexin V/PI staining for flow cytometry
Dead cell removal was performed using negative selection on a MS column following incubation with Dead Cell Removal microbeads (Mitenyi Biotech, USA) as per manufacturer's instructions. Dead cell removal was performed on all samples prior to RNA extraction or DHSs mapping. Annexin V-APC/PI staining (Ebiosciences, USA) or Annexin V-FITC/PI staining (BD Biosciences, USA) was performed according to manufacturer's instructions. Annexin V-APC staining was used for cells that expressed GFP. FACS data were analyzed by Summit 4.3 software (Beckman Coulter).
DNaseI hypersensitivity site mapping
Prior to DNaseI digestion, apoptotic cells were removed using the Dead Cell Removal Kit (Miltenyl Biotech, UK) as per manufacturer's instructions. 3x 10 7 SKH-1 cells were suspended in 1 ml DNase I buffer (0.3M sucrose, 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 10 mM Tris pH7.4). Digestion on 4.5x10 6 cells was performed with DNase I (Worthington, DPPF grade) at 80 units/ml in DNase I buffer with 0.4% NP-40 and 2 mM CaCl2 at 22ºC for 3 minutes. The reaction was stopped with cell lysis buffer (0.3M NaAcetate, 10mM EDTA pH 7.4, 1% SDS) with 1mg/ml Proteinase K and incubated at 45ºC overnight.
For DHS mapping in CD34+ purified t(3;21) patient cells and in SKH-1 transfected with siRNA, lower cell numbers were available and therefore the DNase I concentrations were reduced according to the cell numbers available.
The digested DNase I material was treated with RNAse A (Sigma Aldrich, Germany) at a final concentration of 100 µg/ml at 37ºC for 1 hr. Genomic DNA was extracted using phenol/chloroform method: an equal volume of phenol was added to the reaction and placed on a rotator wheel for 45 minutes. This was centrifuged for 5 minutes at 16000 x g at room temperature. The top layer was transferred to a new tube and the process was repeated sequentially with phenol/chloroform and chloroform. After purification by chloroform extraction, genomic DNA was precipitated with ethanol. This was pelleted by centrifugation for 5 minutes, at 16000 x g at 4°C. The pellet was resuspended with 70% ethanol and centrifugation for 5 minutes, at 16000 x g at 4°C. The pellet was air-dried and dissolved by Tris-EDTA (40 mM Tris Acetate 1 mM EDTA).
Digestion was checked visually by running the samples on a 0.7% agarose gel and by RT-PCR evaluating the ratio of open (TBP promoter) to closed regions of DNA (chromosome 18) and active gene body (beta-actin) to prevent selection of over digested samples (primers in Table S5B ). Subsequently, between 2 to 10 µg of DNase I-digested DNA (depending on material available) were run on a 1.2% agarose gel for selection of shorter fragments to increase the fraction of fragments captured from DHSs. Prior to loading on gel, the purified DNA was treated again with RNAse A (Sigma Aldrich, USA) at a final concentration of 100 µg/ml at 37ºC for 1 hr. 50-300 bp fragments were isolated and purified from the gel using a MinElute gel extraction kit (Qiagen, USA) as per manufacturer's instructions and validated by qPCR as before (Figure 2-1 B-C) . Following this, the size selected sample was validated again by RT-PCR, this time using shorter amplicons to enable detection of the shorter fragments enriched by the size selection process.
Library production of DNase I material for high throughput sequencing After size selection, a library was prepared using Tru-seq DNA sample preparation kit (Illumina, USA) or MicroPlex library preparation kit v2 (Diagenode, Belgium) as per manufacturer's protocol. After PCR a final size selection step was performed by running the library on 1.5% TAE gel, followed by excision of 190-250 bp sized gel fragment. The library was purified from the gel using a MinElute gel extraction kit (Qiagen, USA).
The quality of the libraries was assessed on an Agilent 2100 Bioanalyser. Libraries were subsequently run on two lanes of an Illumina HiSeq 2500 flow-cell for transcription factor footprinting, or as part of 12 indexed libraries in one lane of a NextSeq500 (Illumina, USA) for DHS mapping alone.
ChIP-qPCR and ChIP-Seq library preparation Double cross-linking
A double cross-linking technique was used to optimize the efficiency of transcription factor chromatin immunoprecipitation (ChIP). 2x10 7 cells were washed thrice in PBS. Di(Nsuccinimidyl) glutarate (DSG) (Sigma-Aldrich, Germany) at 850 µg/ml was added to 2x106 cells per ml and were incubated for forty-five minutes. Cells were washed four times and fixed with 1% formaldehyde (Pierce, Thermos Scientific, USA) for ten minutes. Glycine to produce a final concentration of 100mM was added to stop the reaction. The pellet was washed again with PBS. Buffer A (HEPES pH 7.9 10 mM, EDTA 10 mM, EGTA 0.5 mM, Triton x100 0.25%, complete mini protease inhibitor cocktail (PIC) 1x (Sigma-Aldrich, Germany) was added for 10 mins at 4°C and removed by centrifugation at 500 g for 5 minutes. This was repeated with buffer B (HEPES pH 7.9 10 mM, EDTA 1 mM, EGTA 0.5 mM, Triton x100 0.01%, PIC 1x). The residual nuclei were then spun down at 16000 x g at 4°C for 5 minutes and aliquoted at 2x10 7 cells for 4 immunoprecipitations.
Chromatin immunoprecipitation (ChIP)
Each aliquot of 2x10 7 cells was re-suspended in 600 µl of sonication buffer (Tris-HCL pH 8 25 mM, NaCL 150 mM, EDTA 2 mM, Triton 100x 1%, SDS 0.25%, Protease inhibitor cocktail (PIC) 1x). 300 µl of nuclei in sonication buffer was placed in each polystyrene tube and sonicated at 75% amplitude, 26 cycles: 30s on and 30s off per cycle (Q800, Active Motif, USA). Subsequently, 1.2ml of dilution buffer (Tris-HCL pH8 25 mM, NaCL 150 mM, EDTA 2 mM, Triton 100x 1%, glycerol 7.5%, PIC 1x) was added to the pooled post sonication material. This was divided equally between four immunoprecipitations (with 5% of input taken for validation).
15 µl protein G beads (Diagenode, Belgium) were washed twice with 500 µl of 50 mM citrate phosphate buffer and once with 100 mM sodium phosphate). 2 µg antibody (EVI1, C50E12, Cell Signalling, lot 3; or RUNX1, Ab23980, Abcam lot 144722) or 4µg antibody (C/EBPα, A2814 Santa Cruz) was added to 10 µl 100 mM sodium phosphate, 0.5% BSA and incubated with protein G beads at 4°C for 1 hour. Chromatin was then added to the protein G beads with antibody and returned to 4°C for 4 hours. Unbound chromatin was separated from the beads by magnet and the attached beads were washed by buffer 1 (Tris HCL 20 mM, NaCl 150 mM, EDTA 2 mM, Triton x100 1%, SDS 0.1%), twice with buffer 2 (Tris HCL 20 mM, NaCl 500 mM, EDTA 2 mM, Triton x100 1%, SDS 0.1%), LiCL buffer (Tris HCL 10 mM, LiCl 250 mM, EDTA 1 mM, NP40 0.5%, sodium deoxychlolate 0.5%) and finally twice with wash buffer 4 (Tris HCL pH8, 10 mM, NaCl 50 mM, EDTA 1mM). The column was eluted twice with 50 µl buffer (NaHCO3 100 mM and SDS 1%) and the eluant containing the chromatin was pooled. Crosslinks were reversed by incubating the samples at 65°C overnight in 500 mM NaCl, 500 µg/ml proteinase K. DNA was purified by Ampure beads (Beckman Coulter, USA), as above, with the DNA eluted with 50 µl water. Validation of the ChIP was performed by qPCR using a standard curve of genomic DNA from untreated SKH-1 cells (10ng/ µl followed by serial 1:5 dilutions). The input material was diluted 1:5 with water and qPCR was performed as above with primers listed in SI. Validation was analyzed as a ratio of the qPCR signal from the ChIP material over the input.
Library production of ChIP material for high throughput sequencing
Libraries for high throughput sequencing were prepared using the Tru-seq DNA sample preparation kit (Illumina, USA) or Kapa HyperPrep kit (Kapa Biosystems, USA), as per manufacturer's protocol. 18 cycles of PCR was performed and 200-350bp fragments were size selected by running the samples in an agarose gel. Libraries were purified from the gel using a MinElute Gel extraction kit (Qiagen, USA). Libraries were validated by qPCR, with an analysis of the ChIP signal of a positive control region (e.g. PU.1 3H enhancer) over a negative control region (e.g. IVL). Finally, libraries were quantified by Kapa library quantification kit (Kapa Biosystems, USA) and run in a pool of four indexed libraries in one lane of a HiSeq 2500 (Illumina, USA) or 12 indexed libraries in one lane of a NextSeq 500 (Illumina, USA) using 50 cycle single-end reads.
Retroviral production
Lenti-and retroviral transduction pSIEW DNCEBP vector was generated by cloning the DNCEBP insert into the pHR-cppt-SIEW vector (Bomken et al., 2013) . The DNCEBP insert was originally developed by Charles Vinson (NIH, USA) (Krylov et al., 1995) . We used the pSIEW vector backbone (Empty and DNCEBP) to produce lentiviral particles. Packaging and envelope genes were on a separate plasmid to prevent further virus particle generation once transduced into the target cell.
Transfection of HEK293T cells for lentiviral production HEK293T cells were re-plated 24 hour prior to transfection, so that at time of transfection they were 80-90% confluent. On the day of transfection TransIT-293T (Mirius, USA) was brought to room temperature. 
Virus concentration
The virus concentration technique was the same for all viral particles. Viral supernatant was centrifuged at 1660xg 4°C 15 minutes to pellet cell debris. The supernatant was then filtered through a 0.45µm disc filter.
The viral supernatant was concentrated using a Centricon Plus 70 100 kDa filter (Millipore, USA), using the manufacturers instruction. The column was pre-rinsed with sterile water and the column centrifuged at 2000xg, 25 minutes at 4 degrees. The column was then inverted and the concentrate recovered by centrifugation at 1000xg for 2 minutes.
Lentiviral transduction of SKH-1
SKH-1 were transduced with viral concentrates with polybrene at 8 µg/ml by spinoculation at 1500xg for 2 hours at 32°C in non tissue culture treated plates. The plate was subsequently returned to the incubator overnight and at the next morning the viral media was removed and exchanged with fresh media. Viral transduction was estimated by eGFP percentage by flow cytometry 5 days after viral transduction. Cell sorting by FACS was undertaken by sorting for GFP positive cells.
Antibody staining for flow cytometry 15x10 4 were centrifuged at 300xg and washed with MACS buffer. The cell pellet was resuspended in 50 µl MACS buffer and 2 µl of antibody was added and incubated for 15 minutes at 4ºC in the dark. After incubation, the cells was washed once with MACS buffer before resuspension in 300 µl MACS buffer and analyzed on Cyan ADP (Beckman Coulter, USA). Data was analyzed on Summit 4.3 (Beckman Coulter, USA). Antibodies used in this project are listed below.
Whole cell lysate preparation by RIPA buffer lysis
Whole cell lysate was made by lysing 5x10 6 cells using RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.25% Na-deoxycholate, 1% NP40, 1 mM PMSF, complete mini protease inhibitor cocktail (PIC) 1x (Sigma-Aldrich, Germany)). After incubation on ice for 15 minutes, the sample was sonicated for 1 min using a Bioruptor (Diagenode, Belgium) at 4°C.
Nuclear extract
Nuclear extracts were prepared using a co-immunoprecipitation kit (Active Motif, USA). Protein extracts were quantified using Bradford protein reagent (Bio-Rad, USA) and 595nM absorbance quantified by spectrophotometry. Absolute concentrations were determined using a standard curve from a known concentration of BSA (Pierce, USA).
DATA ANALYSIS
ChIP and DNase I sequencing data Analysis Alignment
Sequences from all ChIP and DNase I sequencing experiments in fastq format were mapped onto the reference human genome version hg38, Genome Reference Consortium GRCh38. The quality control statistics for the samples were obtained using FastQC software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The raw reads were aligned to the reference genome using Bowtie2 (Langmead and Salzberg, 2012) . Reads from ChIP-seq data that were uniquely aligned to chromosomal positions were retained and duplicate reads were removed from the aligned data using Picard tools (http://broadinstitute.github.io/picard/). The aligned reads were used to generate density profiles using "genomeCoverageBed" function from bedtools (http://bedtools.readthedocs.org/en/latest/). These tag densities were displayed using the UCSC Genome Browser (Kent et al., 2002) . The numbers of aligned reads are listed in Table S5 . RUNX/ETO ChIP is the combined of a publically available data downloaded from GEO with accession numbers GSM1113429, GSM1113430 (Ben-Ami, et. al, 2013 ) and GSM1082306 (Wang et. al, 2013) .
Peak calling
Regions of enrichment (peaks) of ChIP and DNAse1 sequencing data were identified using DFilter software (Kumar et al., 2013) with recommended parameters (-bs=100 -ks=50 -refine). Peak overlaps, gene annotations were performed using in-house scripts. High confidence ChIP-Seq peaks were defined as those overlapping peaks in the DNase-Seq data. Overlaps between ChIP and DNase l sequencing were defined by requiring the summit of a peak in the ChIP dataset to lie between start and end coordinates of a peak in the DNase l data. Peaks were allocated to genes if located in either their promoters or within the region of 2000 bp downstream and 2000 bp upstream of the transcription start sites (TSS), as intragenic if not in the promoter but within the gene body region, or if intergenic, to the nearest gene located within 100 kb. Overlaps between ChIP-seq peaks were defined by requiring the summits of two peaks to lie within +/-200 bp.
Clustering of ChIP and DNAseI sequencing data
Hierarchical clustering with Euclidean distance and complete linkage clustering was used for clustering of transcription factors based on similar binding patterns of different ChIP-seq data, in SKH-1 cells. The high confidence peaks for all transcriptional factors were intersected and merged when overlapping. The read counts for all union peaks were normalized with regards to total reads depth counts and then Pearson's correlation coefficients were calculated between samples using log2 of the normalized read counts. A correlation matrix was generated and Pearson correlation coefficients are displayed after hierarchical clustering as a heatmap. Colors in the heatmap indicate the strength of association between each pair of transcription factors. Heat maps were generated using Mev from TM4 microarray software suite (Saeed et al., 2006) . Same way was used for DNaseSeq data clustering.
Average tag density profile and heatmap
The tag density and average profiles for Figure 1E were generated by calculating the tag density normalized as coverage per million within 4 kb of the DNAse1 peak summit. The read counts for all union peaks were computed. Coverages were calculated for all union peaks and ranked by log2 fold change. Heatmap images were generated via Java TreeView (http://jtreeview.sourceforge.net/) and average profiles were plotted using R (https://www.rproject.org/).
Motif identification and clustering
De novo motif analysis was performed on peaks using HOMER (Benner et.al 2010) . Motif lengths of 6, 8, 10 , and 12 bp were identified in within ± 200 bp from the peak summit. The top enriched motifs with a significant p value score were recorded. The annotatePeaks function in HOMER was used to find occurrences of motifs in peaks. In this case we used known motif position weight matrices (PWM) from HOMER database.
Motif clustering
Digital footprinting of t(3;21) AML patients 1 and 2 and t(8;21) AML patients 1 and 2 from DNase I high-depth sequencing data was performed using the Wellington algorithm (Piper et al., 2013) with FDR=0.01. For the heatmap that shows hierarchical clustering of motif occurrences within RUNX1/EVI1 footprints ( Figure 3E ), a motif positions search was done within peaks that are only footprinted in t(3;21) patients. The distance between the centers of each motif pairs was calculated and the motif frequency was counted if the first motif was within 50bps distance from the second motif. Z-scores were calculated from the mean and standard deviation of motif frequencies observed in random sets using bootstrap analysis. For bootstrapping, peak sets with a population equal to that of the footprinted peaks were randomly obtained from the union of t(3;21), t(8;21) and CD34+ DNase-Seq footprints. Motif search was repeated for each random set and then the mean and the standard deviation for the total motif frequencies of the random peak sets were calculated and compared with the actual motif frequencies to obtain the Z-scores. A matrix was generated and Z scores were displayed after hierarchical clustering as a heat map. Red color means that motifs are overrepresented and grey color indicates that motif is underrepresented. The same procedure was repeated with RUNX1/ETO and RUNX1 peaks ( Figure S3 and 3F) that are only footprinted in t(8;21) patients and where motif search was done exactly within the footprint coordinates and the random sets were generated from the total patient's footprints.
Motif enrichment
To identify motifs (identified by HOMER) that are relatively enriched in the distal transcription factors (TFs) sites of one cell type compared to another or one TF compared to another from same cell type we considered all possible comparisons ( Figure 3F ), these being TF sites in (A) which are not shared with each of the other TFs (B). For a given set j of TFs, we defined a motif enrichment score (S ij ) for motif i in peak set j as
where n ij is the number of peaks in each subset j (j=1,2,…,12) containing motif i (i=1, 2,….,I) , I is the total number of motifs used in the test, and M j the total number of peaks in each subset j (j=1, 2,…,30) . A matrix was generated and the motif enrichment scores were displayed as a heatmap after hierarchical clustering with Euclidean distance and complete linkage. The heatmap was generated using Mev from TM4 microarray software suite (Saeed et al., 2006) .
RNA-Seq data Analysis
RNA-Seq reads were aligned to the hg38 human genome build using STAR. Separate density profiles for the positive and negative strand were generated for RNA-Seq data. Fragments per Kilobase of transcript per Million mapped reads (FPKM) values for each gene were extracted using Cufflinks and differentially expressed genes were extracted using the limma R package (Ritchie et al., 2015) . All genes with p-value ≤ 0.01 were considered and at least 1.5-fold changes between before and after RUNX1/EVI1 knock down. The differentially expressed genes for the AML patients were considered with at least 2-fold changes using the CD34+ PBSC as a control. The numbers of aligned reads are listed in Table S5 .
The correlation between any two samples was obtained as the Pearson correlation coefficient of expression values over all genes. A correlation matrix was thus generated for all the samples and hierarchically clustered.
Clustering of gene expression was carried out on signal intensity for all expressed genes and on fold-changes for genes associated with at least a 1.5-fold change. Hierarchical clustering was used with Euclidean distance and average linkage clustering. Heatmaps were generated using Mev (Saeed et al., 2006) . The GSEA software (Subramanian et al., 2005) was used to perform gene set enrichment analysis on group of genes. The normalized enrichment score (NES), the p-value and the FDR q-value are displayed on the enrichment plot.
Gene ontology (GO) analysis was performed using Bingo (Maere et al., 2005) and David online tool at david.abcc.ncifcrf.gov (Huang da et al., 2009) using Hypergeometric for overrepresentation and Benjamini and Hochberg (FDR) correction for multiple testing corrections. KEGG Pathway network analysis was performed using clueGO tools (Bindea et al., 2009 ) with kappa score = 0.3. The right-sided enrichment (depletion) test based on the hypergeometric distribution was used for terms and groups. Groups were created by iterative merging of initially defined groups based on the kappa score threshold. The relationship between the selected terms is defined based on their shared genes and the final groups are randomly colored where one, two colors or more represents that a gene/term is a member of Table S1  Table S1 is Table S3 DNA Sequencing data and peak numbers of the experiments indicated in the table below (related to Figures 1,2,3, 6 
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